248 related articles for article (PubMed ID: 29674491)
1. Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.
Ganguly S; Panetta JC; Roberts JK; Schuetz EG
Drug Metab Dispos; 2018 Jul; 46(7):1014-1022. PubMed ID: 29674491
[TBL] [Abstract][Full Text] [Related]
2. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
[TBL] [Abstract][Full Text] [Related]
3. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
[TBL] [Abstract][Full Text] [Related]
4. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
Sato S; Tohyama K; Kosugi Y
Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
[TBL] [Abstract][Full Text] [Related]
5. Pheophorbide A: Fluorescent Bcrp Substrate to Measure Oral Drug-Drug Interactions in Real-Time In Vivo.
Yasuda K; Ganguly S; Schuetz EG
Drug Metab Dispos; 2018 Nov; 46(11):1725-1733. PubMed ID: 30111622
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic and transcriptomic analysis reveals endogenous substrates and metabolic adaptation in rats lacking Abcg2 and Abcb1a transporters.
Ganguly S; Finkelstein D; Shaw TI; Michalek RD; Zorn KM; Ekins S; Yasuda K; Fukuda Y; Schuetz JD; Mukherjee K; Schuetz EG
PLoS One; 2021; 16(7):e0253852. PubMed ID: 34255797
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
8. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
9. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.
Wegler C; Gazit M; Issa K; Subramaniam S; Artursson P; Karlgren M
J Pharm Sci; 2021 Jan; 110(1):388-396. PubMed ID: 33007277
[TBL] [Abstract][Full Text] [Related]
11. Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases.
Gartzke D; Delzer J; Laplanche L; Uchida Y; Hoshi Y; Tachikawa M; Terasaki T; Sydor J; Fricker G
Pharm Res; 2015 Jun; 32(6):2060-71. PubMed ID: 25522789
[TBL] [Abstract][Full Text] [Related]
12. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
13. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Agarwal S; Mittapalli RK; Zellmer DM; Gallardo JL; Donelson R; Seiler C; Decker SA; Santacruz KS; Pokorny JL; Sarkaria JN; Elmquist WF; Ohlfest JR
Mol Cancer Ther; 2012 Oct; 11(10):2183-92. PubMed ID: 22891038
[TBL] [Abstract][Full Text] [Related]
14. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
16. Elevated system exposures of baicalin after combinatory oral administration of rhein and baicalin: Mainly related to breast cancer resistance protein (ABCG2), not UDP-glucuronosyltransferases.
Zhang Y; Zhang M; Hu G; Zhang Z; Song R
J Ethnopharmacol; 2020 Mar; 250():112528. PubMed ID: 31884038
[TBL] [Abstract][Full Text] [Related]
17. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
Zhang Y; Huang J; Liu Y; Guo T; Wang L
Arch Toxicol; 2018 Jun; 92(6):2027-2042. PubMed ID: 29725709
[TBL] [Abstract][Full Text] [Related]
18. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
